

GNOM

Genomics & Biotechnology ETF

ETF Category: Thematic Growth – Technology
As of 03/29/2019



KEY FEATURES



High Growth Potential

GNOM enables investors to access high growth potential through companies that potentially stand to benefit from the increased use of genomic science.



Targeted Exposure

GNOM provides access to emerging areas within the Health Care sector at the intersection of science and technology.



ETF Efficiency

In a single trade, GNOM delivers access to dozens of companies with exposure to the Genomics theme.

FUND DETAILS

Inception Date	4/5/2019
Underlying Index	Solactive Genomics Index
Number of Index Holdings	40
Assets Under Management	-
Total Expense Ratio	0.68%
Distribution Frequency	Semi-Annually

TRADING DETAILS

Ticker	GNOM
CUSIP	37954Y434
Exchange	NASDAQ
Bloomberg IOPV Ticker	GNOMIV
Index Ticker	SOLGNOM

PERFORMANCE (%)

	Current Quarter	Year to Date	One Year	Three Year	Since Inception
GNOM at NAV	-	-	-	-	-
GNOM at Market Price	-	-	-	-	-
Solactive Genomics Index	-	-	-	-	-


The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. Returns for periods greater than one year are annualized. Market price returns are based upon the midpoint of the bid/ask spread at the close of the exchange and do not represent the returns you would receive if you traded shares at other times. For performance data current to the most recent month end, please call 1-888-GXFUND-1 (1-888-493-8631), or visit www.globalxfunds.com.

INDEX TOP 10 HOLDINGS (%)

Holdings Subject to Change


Alnylam Pharmaceuticals, Inc.	4.25%	Qiagen NV	3.99%
Bluebird bio, Inc.	4.08%	Spark Therapeutics, Inc.	3.97%
PTC Therapeutics, Inc.	4.05%	Agilent Technologies, Inc.	3.95%
Ultragenyx Pharmaceutical, Inc.	4.02%	BioMarin Pharmaceutical Inc.	3.93%
Illumina, Inc.	4.01%	Blueprint Medicines Corp	3.92%

INDEX SUB-INDUSTRY BREAKDOWN (%)



Biotechnology	78.88%
Life Sciences Tools & Services	19.11%
Pharmaceuticals	2.01%

INDEX COUNTRY BREAKDOWN (%)



United States	91.39%
China	3.47%
Netherlands	3.29%
Switzerland	1.86%

RISK CHARACTERISTICS SINCE ETF INCEPTION

	Solactive Genomics Index	MSCI ACWI Index
Annualized Volatility	-	-
Beta	-	-
Sharpe Ratio	-	-



DEFINITIONS

Solactive Genomics Index	The Solactive Genomics Index tracks the companies that generate revenues from Genomics related business. Genomics business operations include the following: (i) gene editing (ii) genomic sequencing (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology.
MSCI ACWI Index	MSCI ACWI Index captures large and mid cap representation across 23 Developed Markets (DM) and 24 Emerging Markets (EM) countries. The index covers approximately 85% of the global investable equity opportunity set. DM countries include: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, the UK and the US. EM countries include: Brazil, Chile, China, Colombia, Czech Republic, Egypt, Greece, Hungary, India, Indonesia, Korea, Malaysia, Mexico, Pakistan, Peru, Philippines, Poland, Russia, Qatar, South Africa, Taiwan, Thailand, Turkey and United Arab Emirates.
Annualized Volatility	The annualized standard deviation of the daily returns of the security using the closing levels of the index during the 22 index-day period preceding that day.
Beta	Measures the volatility of the Fund price relative to the volatility in the market index and can also be defined as the percent change in the price of the Fund given a 1% change in the market index. A beta below one suggests that the fund was less volatile than the market benchmark.
Sharpe Ratio	Measures the return for each unit of risk. The risk free rate is subtracted from the mean return and is divided by the standard deviation of returns.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company LLC.

Investing involves risk, including possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified. The information provided is not intended for trading purposes, and should not be considered investment advice.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO nor Global X is affiliated with Solactive AG.

Since the Fund's shares did not trade in the secondary market until several days after the Fund's inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the fund's full or summary prospectus, which may be obtained by calling 1-888-GX-FUND-1 (1.888.493.8631), or by visiting globalxfunds.com. Read the prospectus carefully before investing.